Peregrine Pharmaceuticals (PPHM) Reports In-Line Q4 EPS

Peregrine Pharmaceuticals (NASDAQ: PPHM) reported Q4 EPS of ($0.06), in-line with the analyst estimate of ($0.06). Revenue for the quarter came in at $4.25 million versus the consensus estimate of $3.57 million.

For earnings history and earnings-related data on Peregrine Pharmaceuticals (PPHM) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
• Inhibrx, Inc. (INBX) Misses Q2 EPS by 54c